Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEASE tool trial for stopping anti-TNF therapy in Crohn's disease
NL-OMON54559Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab and adalimumab in Crohn's disease (2 arms), sponsored by Erasmus MC. Primary endpoint: Definition of documented relapse. Started Mar 2021; status: recruiting.
02
Drugs
infliximabadalimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON54559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54559.